Published in Clin Infect Dis on December 15, 2008
Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med (2014) 4.91
Combination antifungal therapy for cryptococcal meningitis. N Engl J Med (2013) 4.87
Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis (2010) 4.08
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis (2010) 2.31
Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis (2010) 2.19
Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS (2010) 2.14
Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis (2013) 2.02
Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr (2012) 1.85
Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One (2011) 1.65
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med (2012) 1.53
Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol (2014) 1.49
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
An update on Cryptococcus among HIV-infected patients. Int J STD AIDS (2010) 1.26
Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. J Int AIDS Soc (2011) 1.24
Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis (2016) 1.22
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS (2012) 1.19
Treatment of cryptococcal meningitis in resource limited settings. Curr Opin Infect Dis (2009) 1.18
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Neurologic complications of HIV disease and their treatment. Top HIV Med (2009) 1.13
Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother (2010) 1.09
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother (2013) 1.09
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother (2015) 1.05
Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis. Open Forum Infect Dis (2015) 1.03
Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol (2014) 1.02
Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis (2013) 1.00
New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS (2013) 0.98
A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. PLoS One (2013) 0.96
Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome(IRIS): Pathogenesis and Its Clinical Implications. Curr Fungal Infect Rep (2011) 0.90
Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa. PLoS One (2010) 0.89
The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health (2013) 0.89
A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS One (2014) 0.85
Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort. Diagn Microbiol Infect Dis (2012) 0.83
Cryptococcal Meningitis: Diagnosis and Management Update. Curr Trop Med Rep (2015) 0.83
Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa. J Acquir Immune Defic Syndr (2016) 0.81
Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgrad Med J (2012) 0.80
Asymptomatic cryptococcemia in resource-limited settings. Curr HIV/AIDS Rep (2013) 0.80
The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya. East Afr Med J (2010) 0.79
Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. Antimicrob Agents Chemother (2009) 0.79
Optimum timing of antiretroviral therapy for HIV-infected patients with concurrent serious opportunistic infections. Clin Infect Dis (2010) 0.78
Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis. Med Mycol (2016) 0.78
Neuromeningeal cryptococcosis in sub-Saharan Africa: Killer disease with sparse data. J Neurosci Rural Pract (2015) 0.76
Opinion: the pharmacometrics of infectious disease. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal Meningitis. J Clin Diagn Res (2015) 0.75
Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis. PLoS One (2017) 0.75
A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. G3 (Bethesda) (2017) 0.75
MORTALITY AFTER CLINICAL MANAGEMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN KENYA. East Afr Med J (2014) 0.75
Integrated therapy for HIV and cryptococcosis. AIDS Res Ther (2016) 0.75
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings. Curr Clin Microbiol Rep (2016) 0.75
Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment clinic in sub-Saharan Africa. BMC Infect Dis (2016) 0.75
Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infect Dis (2015) 0.75
Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. Antimicrob Agents Chemother (2017) 0.75
Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. Expert Rev Anti Infect Ther (2017) 0.75
Cryptococcal meningitis: A neglected NTD? PLoS Negl Trop Dis (2017) 0.75
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Use of clinical algorithms for diagnosing malaria. Trop Med Int Health (2002) 5.77
Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS (2007) 5.54
Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med (2014) 4.91
Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health (2009) 4.69
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Cryptococcal meningitis. Br Med Bull (2005) 3.95
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ (2005) 3.87
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
HIV-associated cryptococcal meningitis. AIDS (2007) 3.18
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis (2011) 2.99
Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis (2010) 2.85
Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr (2010) 2.83
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda. AIDS Behav (2008) 2.53
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis (2010) 2.31
Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr (2009) 2.29
Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med (2013) 2.25
Delay in the diagnosis of pulmonary tuberculosis, London, 1998-2000: analysis of surveillance data. BMJ (2003) 2.09
Improving responsiveness of health systems to non-communicable diseases. Lancet (2013) 2.06
Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med (2011) 2.04
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (2012) 2.02
Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis (2013) 2.02
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Soc Sci Med (2012) 1.88
Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS (2009) 1.85
Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis (2007) 1.83
Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis (2011) 1.83
A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV-infected individuals living in Bangkok. AIDS (2003) 1.79
The potential impact of antiretroviral therapy on fertility in sub-Saharan Africa. Curr HIV/AIDS Rep (2006) 1.77
The Regai Dzive Shiri Project: a cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe--study design and baseline results. Trop Med Int Health (2008) 1.70
Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need? PLoS Med (2013) 1.67
High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS (2009) 1.60
A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J (2007) 1.60
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2009) 1.55
Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis (2014) 1.55
Use of data from HIV counselling and testing services for HIV surveillance in Africa. Lancet (2007) 1.54
Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect (2011) 1.53
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ (2002) 1.52
Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol (2006) 1.51
The Regai Dzive Shiri project: results of a randomized trial of an HIV prevention intervention for youth. AIDS (2010) 1.47
GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS (2013) 1.46
Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS (2002) 1.41
Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One (2013) 1.41
Burden of illness in the first 3 years of life in an Indian slum. J Trop Pediatr (2009) 1.40
Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One (2012) 1.39
Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr (2013) 1.39
Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. AIDS (2010) 1.35
Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. AIDS Res Ther (2011) 1.33
Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis (2005) 1.30
Adherence to antiretroviral therapy in Africa: how high is it really? Trop Med Int Health (2008) 1.30
Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One (2013) 1.29
Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis (2010) 1.29
Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect (2010) 1.28
Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS (2006) 1.27
Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis (2010) 1.26
Reaching millennium development goal 4 - the Gambia. Trop Med Int Health (2011) 1.25
Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res Ther (2011) 1.24
Alcohol use, depressive symptoms and the receipt of antiretroviral therapy in southwest Uganda. AIDS Behav (2007) 1.22
How does antiretroviral treatment attenuate the stigma of HIV? Evidence from a cohort study in rural Uganda. AIDS Behav (2013) 1.21
Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis (2013) 1.19
Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr (2003) 1.19
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS (2012) 1.19
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic) (2012) 1.19
Rates and causes of child mortality in an area of high HIV prevalence in rural South Africa. Trop Med Int Health (2006) 1.18
School based HIV prevention in Zimbabwe: feasibility and acceptability of evaluation trials using biological outcomes. AIDS (2002) 1.18
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother (2011) 1.16
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J (2010) 1.16
ABC for people with HIV: responses to sexual behaviour recommendations among people receiving antiretroviral therapy in Jinja, Uganda. Cult Health Sex (2011) 1.15
Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS (2013) 1.14
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother (2006) 1.13
Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. PLoS Pathog (2011) 1.13
Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis (2013) 1.12
Severe malaria in children in Yemen: two site observational study. BMJ (2006) 1.12
Is sexual contact with sex workers important in driving the HIV epidemic among men in rural Zimbabwe? J Acquir Immune Defic Syndr (2005) 1.11
The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis (2013) 1.11
Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis (2013) 1.11
The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav (2011) 1.10
Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.10
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother (2013) 1.09
Who develops severe malaria? Impact of access to healthcare, socio-economic and environmental factors on children in Yemen: a case-control study. Trop Med Int Health (2008) 1.08